Therefore, the normalization of the vasculature resulting from the administration of anti-endoglin therapies may reduce tumor cell intravasation and increase the effectiveness of chemotherapy, as has already been observed with anti-VEGF and ALK1-Fc treatments [47, 53, 54]. The gene discussed is VEGFA; the disease is neoplasm.